SPY299.08+3.64 1.23%
DIA250.25+5.37 2.19%
IXIC9,340.22+15.63 0.17%

Jefferies Maintains Buy on Esperion Therapeutics, Lowers Price Target to $70

Jefferies maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $85 to $70.

Benzinga · 05/07/2020 17:32

Jefferies maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $85 to $70.